TC BioPharm Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Other income

Other income

12 Months Ended

Dec. 31, 2021

4.	Other income

Schedule of other (expenses) income

	Year ended December 31,		Year ended December 31,		Year ended December 31,
	2021		2020		2019
	£		£		£
Grant income		6,381		547,928		1,163,624
Other income		-		21,272		397,642
Other (expenses)/income		6,381		569,200		1,561,266

Grant income received in the years ended December 31, 2021 and 2020 was represented by payments under the Coronavirus Job Retention Scheme. Grant income received in the year ended December 31, 2019 was represented by research and development related grant funding.

Unrealized exchange differences in the period relate to retranslation of the US dollar denominated convertible loan notes as at the period end.

Other income includes research and development tax credits totaling £Nil (2020: £6,772 and 2019: £394,642).

TC BIOPHARM (HOLDINGS) PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)